TY - JOUR T1 - ANA-negative Antitopoisomerase I Antibody Is Not Generally Accepted JF - The Journal of Rheumatology JO - J Rheumatol SP - 1546 LP - 1546 DO - 10.3899/jrheum.190524 VL - 46 IS - 11 AU - LA-HE JEARN AU - THINK-YOU KIM Y1 - 2019/11/01 UR - http://www.jrheum.org/content/46/11/1546.abstract N2 - To the Editor:Recently, Tebo and colleagues suggested that low titer antitopoisomerase I antibody (anti-topo I) including antinuclear antibody (ANA)-negative through multiplex bead assay can be of clinical significance and indicative of the pathogenesis of pulmonary epithelial damage1. This suggestion deeply worries us because it may have resulted from a lack of understanding of the methodology.New sensitive methods have been applied to antiextractable nuclear antigen (anti-ENA) tests; however, their specificity has been low, making their original clinical significance unclear. In similar cases, we have previously pointed out issues related to anti-Sm and antiribosomal P2,3, and a reminder is necessary that the clinical significance of the anti-ENA test (including anti-topo I) was established by the double immunodiffusion method4.In the study by Tebo and colleagues1, the median … Address correspondence to Dr. T.Y. Kim, Department of Laboratory Medicine, College of Medicine, Hanyang University, 222-1 Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea. E-mail: tykim{at}hanyang.ac.kr ER -